Radiopharm Theranostics Advances in Clinical Trials and Secures Major Investment
I'm PortAI, I can summarize articles.
Radiopharm Theranostics Limited (AU:RAD) announced advancements in clinical trials and a significant investment from Lantheus Holdings Inc., which increased its stake to 12.16% with a US$5 million placement. The company reported successful detection of brain metastases using RAD 101 and positive preclinical data for RAD202, enhancing its position in the radiopharmaceutical industry. Radiopharm focuses on developing products for cancer diagnostics and treatment, with ongoing trials for various solid tumors. Current market cap is A$49.01M, with a year-to-date price performance of 5.00%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments